Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radioprotective effects of the immunomodulator AS101.
Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Seghal SN, Sredni B. Kalechman Y, et al. Among authors: gurwith m. J Immunol. 1990 Sep 1;145(5):1512-7. J Immunol. 1990. PMID: 2384668
Immunologic effects of AS101 in the treatment of cancer patients.
Shani A, Tichler T, Catane R, Gurwith M, Rozenszajn LA, Gezin A, Levi E, Schlesinger M, Kalechman Y, Michlin H, et al. Shani A, et al. Among authors: gurwith m. Nat Immun Cell Growth Regul. 1990;9(3):182-90. Nat Immun Cell Growth Regul. 1990. PMID: 2370878
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B, Patel KS, Smith K, Walker R, Wang C, Greene AM, Smith G, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO; (ex-V3SWG). Wilkinson B, et al. Among authors: gurwith m. Vaccine. 2023 Oct 26;41(45):6762-6773. doi: 10.1016/j.vaccine.2023.07.040. Epub 2023 Sep 20. Vaccine. 2023. PMID: 37739888 Free article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Estephan L, Liu LT, Lien CE, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO ex-V3SWG). Estephan L, et al. Among authors: gurwith m. Vaccine. 2023 Apr 6;41(15):2615-2629. doi: 10.1016/j.vaccine.2023.02.083. Epub 2023 Mar 3. Vaccine. 2023. PMID: 36925422 Free PMC article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B, Straus W, White P, Leav A, Gaines T, Maggiacomo G, Kim D, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO ex-V3SWG. Leav B, et al. Among authors: gurwith m. Vaccine. 2022 Aug 19;40(35):5275-5293. doi: 10.1016/j.vaccine.2022.06.005. Epub 2022 Jun 9. Vaccine. 2022. PMID: 35753841 Free PMC article.
141 results